Regulation of Αlpha-Synuclein Gene (SNCA) by Epigenetic Modifier TET1 in Parkinson Disease
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: Deregulation of SNCA encoding α-synuclein (α-SYN) has been associated with both the familial and sporadic forms of Parkinson disease (PD). Epigenetic regulation plays a crucial role in PD. The intron1 of SNCA harbors a large unmethylated CpG island. Ten-eleven translocation methylcytosine dioxygenase 1 (TET1), a CpG island binding protein, can repress gene expression by occupying hypomethylated CpG-rich promoters, and therefore SNCA could be a target for TET1. We investigated whether TET1 binds to SNCA-intron1 and regulates gene expression. Methods: The dopaminergic neuronal cell line, ReNcell VM, was used. Reverse transcription-polymerase chain reaction (RTPCR), real time-quantitative PCR, Western blot, dot-blot, and Chromatin immunoprecipitation were conducted. The substantia nigra tissues of postmortem PD samples were used to confirm the level of TET1 expression. Results: In the human dopaminergic cell line, ReNcell VM, overexpression of the DNA-binding domain of TET1 (TET1- CXXC) led to significant repression of α-SYN. On the contrary, knocking down of TET1 led to significantly higher expression of α-SYN. However, overexpression of the DNA-hydroxymethylating catalytic domain of TET1 failed to change the expression of α-SYN. Altogether, we showed that TET1 is a repressor for SNCA, and a CXXC domain of TET1 is the primary mediator for this repressive action independent of its hydroxymethylation activity. TET1 levels in PD patients are significantly lower than that in the controls. Conclusions: We identified that TET1 acts as a repressor for SNCA by binding the intron1 regions of the gene. As a high level of α-SYN is strongly implicated in the pathogenesis of PD, discovering a repressor for the gene encoding α-SYN is highly important for developing novel therapeutic strategies for the disease.
Abstract
Purpose: Deregulation of SNCA encoding α-synuclein (α-SYN) has been associated with both the familial and sporadic forms of Parkinson disease (PD). Epigenetic regulation plays a crucial role in PD. The intron1 of SNCA harbors a large unmethylated CpG island. Ten-eleven translocation methylcytosine dioxygenase 1 (TET1), a CpG island binding protein, can repress gene expression by occupying hypomethylated CpG-rich promoters, and therefore SNCA could be a target for TET1. We investigated whether TET1 binds to SNCA-intron1 and regulates gene expression. Methods: The dopaminergic neuronal cell line, ReNcell VM, was used. Reverse transcription-polymerase chain reaction (RTPCR), real time-quantitative PCR, Western blot, dot-blot, and Chromatin immunoprecipitation were conducted. The substantia nigra tissues of postmortem PD samples were used to confirm the level of TET1 expression. Results: In the human dopaminergic cell line, ReNcell VM, overexpression of the DNA-binding domain of TET1 (TET1- CXXC) led to significant repression of α-SYN. On the contrary, knocking down of TET1 led to significantly higher expression of α-SYN. However, overexpression of the DNA-hydroxymethylating catalytic domain of TET1 failed to change the expression of α-SYN. Altogether, we showed that TET1 is a repressor for SNCA, and a CXXC domain of TET1 is the primary mediator for this repressive action independent of its hydroxymethylation activity. TET1 levels in PD patients are significantly lower than that in the controls. Conclusions: We identified that TET1 acts as a repressor for SNCA by binding the intron1 regions of the gene. As a high level of α-SYN is strongly implicated in the pathogenesis of PD, discovering a repressor for the gene encoding α-SYN is highly important for developing novel therapeutic strategies for the disease.
참고문헌 (35)
- Xu L, "Alpha-synuclein in Parkinson’s disease : from pathogenetic dysfunction to potential clinical application", Parkinsons Dis, 2016, pp.1720621~ (2016)
- Goedert M, "100 years of Lewy pathology", Nat Rev Neurol, 9, pp.13~24 (2013)
- Guhathakurta S, "Deregulation of alpha-synuclein in Parkinson’s disease : Insight from epigenetic structure and transcriptional regulation of SNCA", Prog Neurobiol, 154, pp.21~36 (2017)
- Gründemann J, "Elevated alphasynuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson’s disease", Nucleic Acids Res, 36, pp.e38~ (2008)
- Brice A, "Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease", Lancet, 364, pp.1169~1171 (2004)
- Singleton AB, "Alpha-synuclein locus triplication causes Parkinson’s disease", Science, 302, pp.841~ (2003)
- Chartier-Harlin MC, "Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease", Lancet, 364, pp.1167~1169 (2004)
- Clough RL, "Functional dissection of the alpha-synuclein promoter : transcriptional regulation by ZSCAN21and ZNF219", J Neurochem, 110, pp.1479~1490 (2009)
- Duplan E, "Direct alphasynuclein promoter transactivation by the tumor suppressor p53", Mol Neurodegener, 11, pp.13~ (2016)
- Jowaed A, "Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains", J Neurosci, 30, pp.6355~6359 (2010)
- Matsumoto L, "CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson’s disease", PLoS One, 5, pp.e15522~ (2010)
- Scherzer CR, "GATA transcription factors directly regulate the Parkinson’s disease-linked gene alpha-synuclein", Proc Natl Acad Sci U S A, 105, pp.10907~10912 (2008)
- Chiba-Falek O, "Regulation of alpha-synuclein expression by poly(ADP ribose)polymerase-1(PARP-1)binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene", Am J Hum Genet, 76, pp.478~492 (2005)
- Soldner F, "Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates target gene expression", Nature, 533, pp.95~99 (2016)
- Kabaria S, "Inhibition of miR-34b and miR-34c enhances alpha-synuclein expression in Parkinson’s disease", FEBS Lett, 589, pp.319~325 (2015)
- Mikkelsen TS, "Genome-wide maps of chromatin state in pluripotent and lineage-committed cells", Nature, 448, pp.553~560 (2007)
- Guhathakurta S, "Hypomethylation of intron1 of alpha-synuclein gene does not correlate with Parkinson’s disease", Mol Brain, 10, pp.6~ (2017)
- De Boni L, "Next-generation sequencing reveals regional differences of the alpha-synuclein methylation state independent of Lewy body disease", Neuromolecular Med, 13, pp.310~320 (2011)
- Richter J, "No evidence for differential methylation of alpha-synuclein in leukocyte DNA of Parkinson’s disease patients", Mov Disord, 27, pp.590~591 (2012)
- Song Y, "Pyrosequencing analysis of SNCA methylation levels in leukocytes from Parkinson’s disease patients", Neurosci Lett, 569, pp.85~88 (2014)
- He YF, "Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA", Science, 333, pp.1303~1307 (2011)
- Ito S, "Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine", Science, 3333, pp.1300~1303 (2011)
- Tahiliani M, "Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1", Science, 324, pp.930~935 (2009)
- Kriaucionis S, "The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain", Science, 324, pp.929~930 (2009)
- Wu X, "TET-mediated active DNA demethylation: mechanism, function and beyond", Nat Rev Genet, 18, pp.517~534 (2017)
- Wu H, "Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells", Nature, 473, pp.389~393 (2011)
- Williams K, "TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity", Nature, 473, pp.343~ (2011)
- Frauer C, "Different binding properties and function of CXXC zinc finger domains in Dnmt1 and Tet1", PLoS One, 6, pp.e16627~ (2011)
- Jin C, "TET1is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells", Nucleic Acids Res, 42, pp.6956~6971 (2014)
- Xu Y, "Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells", Mol Cell, 42, pp.451~464 (2011)
- Bernstein BE, "A bivalent chromatin structure marks key developmental genes in embryonic stem cells", Cell, 125, pp.315~326 (2006)
- Cristóvão AC, "NADPH oxidase 1 mediates alpha-synucleinopathy in Parkinson’s disease", J Neurosci, 32, pp.14465~14477 (2012)
- Guhathakurta S, "Targeted attenuation of elevated histone marks at SNCA alleviates alpha-synuclein in Parkinson’s disease", EMBO Mol Med, 13, pp.e12188~ (2021)
- Basu S, "A novel tool for monitoring endogenous alpha-synuclein transcription by NanoLuciferase tag insertion at the 3’end using CRISPR-Cas9 genome editing technique", Sci Rep, 8, pp.45883~ (2018)
- Guo JU, "Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain", Cell, 145, pp.423~434 (2011)